par Bertini, Enrico;Dessaud, Eric;Mercuri, Eugenio;Muntoni, Francesco;Kirschner, Janbernd;Reid, Carol;Lusakowska, Anna;Deconinck, Nicolas ;Cuisset, Jean Marie;Abitbol, Jean-Louis;Scherrer, Bruno;Ducray, Patricia Sanwald;Buchbjerg, Jeppe;Vianna, Eduardo;van der Pol, Ludo WL;Vuillerot, Carole;Blaettler, Thomas;Fontoura, Paulo;Olesoxime SMA Phase 2 Study Investigators,
Référence Lancet neurology, 16, 7, page (513-522)
Publication Publié, 2017-07
Référence Lancet neurology, 16, 7, page (513-522)
Publication Publié, 2017-07
Article révisé par les pairs
Titre: |
|
Auteur: | Bertini, Enrico; Dessaud, Eric; Mercuri, Eugenio; Muntoni, Francesco; Kirschner, Janbernd; Reid, Carol; Lusakowska, Anna; Deconinck, Nicolas; Cuisset, Jean Marie; Abitbol, Jean-Louis; Scherrer, Bruno; Ducray, Patricia Sanwald; Buchbjerg, Jeppe; Vianna, Eduardo; van der Pol, Ludo WL; Vuillerot, Carole; Blaettler, Thomas; Fontoura, Paulo; Olesoxime SMA Phase 2 Study Investigators, |
Informations sur la publication: | Lancet neurology, 16, 7, page (513-522) |
Statut de publication: | Publié, 2017-07 |
Sujet CREF: | Sciences bio-médicales et agricoles |
MeSH keywords: | Adolescent |
Adult | |
Child | |
Child, Preschool | |
Cholestenones -- administration & dosage -- adverse effects -- pharmacology | |
Double-Blind Method | |
Female | |
Humans | |
Male | |
Mobility Limitation | |
Neuroprotective Agents -- administration & dosage -- adverse effects -- pharmacology | |
Outcome Assessment (Health Care) | |
Spinal Muscular Atrophies of Childhood -- drug therapy -- physiopathology | |
Young Adult | |
Langue: | Anglais |
Identificateurs: | urn:issn:1474-4422 |
info:doi/10.1016/S1474-4422(17)30085-6 | |
info:pii/S1474-4422(17)30085-6 | |
info:pmid/28460889 |